New Therapeutic Options in the Management of Hepatitis C (HCV): Optimized Clinical and Economic Strategies for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2019 to February 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
AbbVie

Description:
Hepatitis C virus (HCV) infection is the most common chronic blood borne infection in the United States. Today, approximately 3.5 million persons in the United States are chronically infected with this disease and are at risk for the development of extrahepatic manifestations, compensated and decompensated cirrhosis, and hepatocellular carcinoma. Fortunately for patients with HCV, newer treatments have become available or are undergoing regulatory review, with shorter treatment time, increased efficacy and fewer side effects. Direct acting antiviral agents (DAA’s) are oral drugs that have fewer major side effects. In recent clinical trial data, some newer combination treatments have shown the ability to provide a virologic cure in as little as 8 weeks, significantly reducing the time that patients would need to be on a treatment regimen, thus making patient compliance much easier to maintain and improving patient outcomes. It is critical that health care professionals are updated on all the new data and information surrounding these new options.

Upon completion of this activity, participants will be able to:

  • Explore the mechanisms of action, efficacy and safety of newer antiviral agents for the treatment of HCV

  • Assess the role of oral HCV combination therapies in optimizing barriers to resistance

  • Identify emerging treatments for patients with HCV and comorbidities, complications, prior treatment experience, and varying HCV genotypes based on the latest guidelines and relevant clinical data

  • Assess the managed care considerations of newer oral antivirals by exploring where these agents fit into current HCV management paradigm

  • Discuss evaluation and prevention strategies for HCV infection in higher-risk patients, including those with advanced chronic kidney disease (CKD)

  • Incorporate institutional strategies that facilitate the appropriate use of newer and emerging HCV therapies
     

Faculty: David Winston, MD, FACP
Section Head, Gastroenterology & Hepatology
Cigna Healthcare

Disclosure:

Dr. Winston has no relevant financial relationships to disclose. His presentation has been reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
AbbVie

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue